lululemon Expands International Presence with First Store Opening in Italy
VANCOUVER, British Columbia — lululemon (NASDAQ:LULU) continues to grow its international footprint with the upcoming launch of its first store in Italy, which will be opening in the heart of Milan's iconic shopping district on Saturday, July 19, 2025. Located at Vittorio Emanuele II 24/28, the new store will introduce lululemon's innovative athletic apparel and accessories to the Italian market, furthering the brand's vision to unlock greater possibility and wellbeing for all.
Article content
Article content
The Milan store's full concept will span approximately 5,700 square feet across two floors, offering a thoughtfully curated environment for guests with distinct spaces dedicated to lululemon's signature technical innovations. The two floors will showcase the brand's men's and women's collections – all designed through the lens of high-performance, high-style to support a wide range of activities including yoga, running, training, tennis, and golf.
Article content
Paying homage to Italy's rich design heritage, the store is expected to feature a locally inspired architectural concept that blends traditional craftsmanship with contemporary materials. A standout feature of the new store is anticipated to be the lululemon Glide sculptural façade – a striking visual expression of movement and form. The custom 3-D printed installation is set to draw inspiration from lululemon's iconic Define Jacket pattern, and its flowing geometry is designed to expand and move across the storefront, emulating the properties of fabric on an architectural scale.
Article content
In line with lululemon's omni-channel vision, the Milan store aims to offer a fully integrated guest experience. Guests can enjoy seamless access to the brand's full range via the Endless Aisle BBR (Back Back Room) solution, which is designed to help ensure availability of product beyond what is stocked in-store.
Article content
International visitors will benefit from Global Blue Tax-Free Shopping, further enhancing the guest experience in one of Europe's most popular tourist destinations.
Article content
Strategic Growth Across EMEA
Article content
The Milan store opening marks a significant step in lululemon's international expansion. The brand already operates stores in key markets including the UK, Ireland, Germany, France, Spain, the Netherlands, Norway, Sweden, and Switzerland. Entering Italy is part of lululemon's broader Power of Three ×2 growth plan, which aims to quadruple international revenue from 2021 levels by year-end 2026.
Article content
Building Community
Article content
lululemon is grounded in product innovation, guest experience, and a deep commitment to building meaningful connections. In Milan, the brand expects to engage with the local community through a series of activations planned throughout the year, which may include partnerships with local studios, run clubs, and a new ambassador program. These initiatives are intended to reflect lululemon's holistic approach to wellbeing – supporting the physical, mental, and social health of the community it serves.
Article content
About lululemon
Article content
lululemon (NASDAQ:LULU) is a technical athletic apparel, footwear, and accessories company for yoga, running, training, tennis, golf, and other activities. It creates transformational products and experiences that build meaningful connections, unlocking greater possibility and wellbeing for all. Setting the bar in innovation of fabrics and functional designs, lululemon works with athletes in local communities around the world for continuous research and product feedback. For more information about lululemon's Milan opening and latest product collections, visit eu.lululemon.com or follow @lululemoneurope on social media.
Article content
Forward-looking statements:
Article content
This press release contains forward-looking statements, which reflect lululemon's current expectations and plans. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could affect our future performance are included in our filings with the Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q, and 8-K. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of this release.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Bayer AG's Exploratory Study on Sepsis and DIC: A Potential Game-Changer?
Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bayer AG is conducting an exploratory study titled 'Exploratory Study to Investigate the Association Between the Onset of Disseminated Intravascular Coagulation (DIC) and Disease Progression With Different Biomarker Candidates as Well as Standard Clinical and Demographic Parameters in Adult Patients With Sepsis.' The study aims to understand how sepsis progresses to DIC, a severe blood disorder, by identifying biomarkers in patients admitted to intensive care units across Europe. This research is significant due to the limited treatment options for DIC, especially in sepsis patients. The study involves no investigational treatments; instead, participants receive standard medical care for sepsis. The focus is on collecting blood samples and clinical data to identify biomarkers indicative of DIC development. Designed as an interventional study with a single-group model, this research does not involve masking and primarily seeks to gather observational data. The study's primary purpose is to explore the progression of sepsis to DIC. The study began on January 29, 2025, with primary completion expected within 56 days for each participant. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and data collection. This study could impact Bayer's stock performance by potentially enhancing its reputation in the medical research field, especially if the findings lead to improved understanding and treatment of sepsis-related DIC. Investors may view this as a positive development, although the absence of new drug interventions limits immediate commercial implications. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
4 hours ago
- Globe and Mail
AstraZeneca's Osimertinib Study: A Potential Game-Changer for NSCLC Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a study titled 'Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France' to evaluate the effectiveness of osimertinib in treating locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating EGFR mutations. The study aims to assess the 36-month overall survival rate, patient characteristics, disease progression, treatment patterns, and quality of life. The intervention being tested is osimertinib, a drug used as a first-line treatment for NSCLC patients with specific genetic mutations. It is designed to target and inhibit the growth of cancer cells. This observational study employs a multicenter design, combining a cross-sectional survey and a prospective cohort model. It focuses on real-life treatment scenarios to gather comprehensive data on patient outcomes and treatment efficacy. The study began on May 12, 2021, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and ensuring timely analysis of the data collected. The study's findings could significantly impact AstraZeneca's stock performance by demonstrating the effectiveness of osimertinib, potentially boosting investor confidence. It also positions AstraZeneca competitively within the oncology market, particularly against other companies developing treatments for NSCLC. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
6 hours ago
- Globe and Mail
New Buy Rating for SAP SE (0NW4), the Technology Giant
In a report released today, Sven Merkt from Barclays maintained a Buy rating on SAP SE, with a price target of €275.00. The company's shares closed yesterday at €245.83. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Merkt is a 3-star analyst with an average return of 2.2% and a 53.42% success rate. Merkt covers the Technology sector, focusing on stocks such as Temenos, Sage Group plc, and Adyen. Currently, the analyst consensus on SAP SE is a Strong Buy with an average price target of €299.65, which is a 21.89% upside from current levels. In a report released on July 23, Deutsche Bank also maintained a Buy rating on the stock with a €310.00 price target. 0NW4 market cap is currently €287.2B and has a P/E ratio of 44.29. Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0NW4 in relation to earlier this year.
